Nubeqa

News

ESMO26: Bayer's Nubeqa finds new prostate cancer role

Bayer's prostate cancer drug Nubeqa has reduced the risk of the disease spreading or death by 58% in patients at high risk of disease recurrence.

News

A male HCP discusses treatment with an older male patient

Bayer's prostate cancer drug Nubeqa cleared for NHS use

Thousands of men living with incurable prostate cancer will be able to access an easier-to-tolerate treatment from Bayer, thanks to new NICE guidance.

News

Bayer CEO confident firm can cope with Xarelto hit

Bayer's CEO says new product launches will offset the decline in sales of anticoagulant Xarelto over the course of 2025.

News

Bayer CEO says recovery on track as key drug products shine

Bayer has joined its peers among European drugmakers with a hike in pharma forecasts for the year, as it recorded a rise in group sales, but lower profits for the second quarter.

News

Trial sets up wider use of Bayer's Nubeqa in prostate cancer

Bayer has the result it was hoping for in the phase 3 ARANOTE trial of Nubeqa in metastatic, hormone-sensitive prostate cancer (mHSPC), a key part of its plan to build the drug into a €3 bi

News

MHRA, NHS England make available new prostate cancer treatme...

Jointly Bayer and Orion Corporation-developed NUBEQA (Darolutamide) + Androgen Deprivation Therapy (ADT) in combination with docetaxel is to be the first prostate cancer treatment to be mad

ESMO26: Bayer's Nubeqa finds new prostate cancer role

Bayer's prostate cancer drug Nubeqa cleared for NHS use

Bayer CEO confident firm can cope with Xarelto hit

Bayer CEO says recovery on track as key drug products shine

Trial sets up wider use of Bayer's Nubeqa in prostate cancer

MHRA, NHS England make available new prostate cancer treatme...

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Discover a new era of healthcare panel engagement: Grounded ...

Nubeqa

Editor's Picks